U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Moy-Fincher Medical Group - 440852 - 02/08/2018
  1. Warning Letters

CLOSEOUT LETTER

Moy-Fincher Medical Group MARCS-CMS 440852 —

Recipient:
Moy-Fincher Medical Group

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

5001 Campus Drive
College Park, MD 20740
 
 

FEB 8, 2018

Ronald L. Moy
DNA EGF Renewal
421 N. Rodeo Dr. Suite T-7
Beverly Hills, CA 90210

Dear Mr. Moy:

The Food and Drug Administration has completed an evaluation of your firm 's corrective actions in response to our Warning Letter #440852 issued February 12, 2015. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This Jetter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Latasha A. Robinson
Branch Chief
Dietary Supplements & Labeling Assessment Branch
Office of Compliance
Center for Food Safety
     and Applied Nutrition 

Back to Top